SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Veltheer who wrote (303)10/22/1998 7:44:00 PM
From: Steven Yang  Read Replies (1) of 328
 
NXTR Investors: (continued)

With the earning report, (and the extra income from the deal with SKW) I expected that NXTR would be received very warmly today. However, this did not happen.

Now comes the troubling/confusing part, to me at least. I could not find what is the bears' case on NXTR. There are bears out there for NXTR, given the 2.6M short interest. As a matter fact, about 50K new short position was initiated last month even when NXTR was traded at $8 or less. What did the shorts see that I/we/the longs do not?

The only reason that I could think of was the speculations by the bears that NXTR will lose its sale in the face of competition. If that is the case, the 98Q3 earning report has settled the issue. NXTR's product sale has continued to grow, and the growth is expected to continue, albert at a slower pace.

What could be the other reasons? Any comments are appreciated.

Steven

ps: I have given NXTR a value of $18 based on its product sale, cash ($60M), PASS technology, and pipeline (mainly MK).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext